{"id":"NCT04049760","sponsor":"Amicus Therapeutics","briefTitle":"Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease","officialTitle":"A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-11","primaryCompletion":"2024-11-29","completion":"2024-11-29","firstPosted":"2019-08-08","resultsPosted":"2025-06-17","lastUpdate":"2025-06-17"},"enrollment":16,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"DRUG","name":"migalastat HCl 150 mg","otherNames":["migalastat","AT1001"]}],"arms":[{"label":"migalastat HCl 150 mg","type":"EXPERIMENTAL"}],"summary":"This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \\> 12 Years of Age With Fabry Disease and Amenable GLA Variants","primaryOutcome":{"measure":"Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug","timeFrame":"Entire study","effectByArm":[{"arm":"Migalastat HCl 150 mg","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":6,"countries":["United States","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Covid-19","Nasopharyngitis","Aspartate aminotransferase increased","Dizziness","Cough"]}}